Opinion|Videos|November 19, 2024

Elinzanetant and the OASIS Trials: Quality of Life and Symptom Relief

Name: Elinzanetant and the OASIS Trials: Quality of Life and Symptom Relief
Uploaded: 2024-11-19T13:00:00.000Z
Duration: pt9m15s
Description: Elinzanetant and the OASIS Trials: Quality of Life and Symptom Relief

Author(s)Ryan Haumschild, PharmD, MS, MBA, CPEL, JoAnn V. Pinkerton, MD, FACOG, MSCP , Alexa N. Fiffick, DO, MBS, MSCP

Key Takeaways

Elinzanetant showed significant efficacy in reducing VMS frequency and severity, with rapid symptom improvement compared to other treatments.
The trials highlighted elinzanetant's positive impact on quality of life for women with severe VMS.
Notable adverse events were observed, and the safety profile was compared with fezolinetant and traditional treatments, indicating its potential as an alternative.

Panelists discuss the methodologies of the OASIS 1, 2, and 3 trials that investigated elinzanetant, highlighting key findings regarding its efficacy in reducing the frequency and severity of vasomotor symptoms (VMS) compared with other treatments, as well as its impact on quality of life and the speed at which patients experienced symptom improvement.

Video content above is prompted by the following:

(PINKERTON) Elinzanetant was studied in the OASIS 1 and 2 trials, and new data on OASIS 3 were just presented at The Menopause Society’s 2024 Annual Meeting. What was the methodology of these studies?
(SMITH) What are the key findings from the OASIS trials in terms of the reduction in frequency and severity of VMS, and how do these compare with other hormonal and nonhormonal treatments?
1. How did elinzanetant impact quality of life for women with severe VMS in the OASIS trials?
2. How quickly did patients experience an improvement in symptoms?
(PINKERTON) What notable adverse events were observed in the OASIS trials with elinzanetant?
(FIFFICK) How do these safety profiles of elinzanetant and fezolinetant compare with traditional treatments?

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Elinzanetant and the OASIS Trials: Quality of Life and Symptom Relief

Key Takeaways

Newsletter

Latest CME

From Strict Avoidance to Tailored Therapies: Transforming Food Allergy Care

The Evolving Strategies for Managing nAMD and DME: Empowering Managed Care Decisions for Improved Patient Outcomes

Managing Schizophrenia: Evidence-Based Care and Optimizing Value of New and Emerging Therapies

Closing Gaps in CLL Care: Managed Care Insights and Strategies

Revolutionizing Acute Pain Relief: Emerging Non-Opioid Therapies and the Essential Role of Pharmacists

Overview and Burden of Migraine

The Role of the Pharmacist Migraine Management

The Evolving Treatment Landscape of Migraine

Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

New and Approved: FDA’s 2024 Drug Lineup

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

Leveraging Managed Care to Optimize Patient Outcomes: Integrating Novel Treatments in Schizophrenia

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens

Exploring Therapeutic Advances in Myelofibrosis and Key Considerations for Effective Management

Driving Better Outcomes in Hypertrophic Cardiomyopathy: A Managed Care Imperative

Optimizing the Uptake of Long-Acting Injectables in HIV Treatment and Prevention: Considerations for Managed Care

Harnessing Data-Driven Insights and Innovations to Enhance AMD and DME Management: Strategic Approaches for Managed Care

Navigating the Advancements in Oral Therapy Options in HR+ Metastatic Breast Cancer

Navigating the Changing Treatment Paradigm of Metabolic Dysfunction-Associated Steatohepatitis: A Guide for Managed Care Pharmacists

Managed Care Approaches and Models for Equitable Access to Innovations in Major Depressive Disorder Treatment

Evaluating the Effectiveness and Value of Novel Nonhormonal Treatments in the Management of Menopause-Related Vasomotor Symptoms

Updated Guidance and Managed Care Strategies to Optimize Respiratory Syncytial Virus Vaccination Coverage

Leveraging Biologics and Immunotherapies in the Management of Food Allergies

Advancing Care in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Optimizing Outcomes With Emerging Therapies

The Evolving Landscape of Transthyretin Amyloidosis Cardiomyopathy: New Therapies and Treatment Strategies

Reflecting on the Real-World Use of Biologic Therapy in Asthma Management

Advancing Cystic Fibrosis Management: The Evolving Role of Specialty and Managed Care Pharmacists

Pulmonary Arterial Hypertension: Real-World Applications of New Therapies and Management Strategies

Targeting Chronic Rhinosinusitis With Nasal Polyps With Biologics: Optimizing Outcomes and Reducing Health Care Burden

Emerging Treatment Options for Inflammatory Bowel Disease: A Focus on IL-23 Pathway Inhibition

Transforming Metabolic Dysfunction-Associated Steatohepatitis Management: Pharmacist Considerations for the Evolving Treatment Landscape

Innovations in Inflammatory Bowel Disease Therapy: How IL-23 Inhibitors Are Shaping Treatment and Managed Care Approaches

The Expanding Therapeutic Landscape in IgA Nephropathy: Applying Evidence-Based Strategies and Guideline Updates for Managed Care

Leveraging Novel Therapies to Transform Demodex Blepharitis Care (Pharmacy Technician Credit)

Leveraging Novel Therapies to Transform Demodex Blepharitis Care

The Changing Paradigm in Pain Management and Supporting Access to Novel Therapies

The Expanding Therapeutic Landscape in IgA Nephropathy: A Case-Based Exploration of Optimized Patient Outcomes

Opioids, Pain Management, and Substance Use Disorder: A Practical Overview

Trending on AJMC

2025 Nobel Prize in Medicine Honors Discoveries Behind Regulatory T Cells

FDA Expands Roflumilast Use for Atopic Dermatitis to Children Aged 2 to 5 Years

Aggressive Therapy Recommendations Following the STRONG-HF Trials: Stephen J. Green, MD

Pricing and Insurance Networks in Outpatient Surgery Markets

Mediterranean Diet Improves Psoriasis Severity, Study Finds